Clinical trials: Venous Thromboembolic Event
Venous Thrombosis (Disorder)
Patient Education Bundle vs. Nurses Feedback and Coaching to Prevent Missed Doses of VTE Prophylaxis
VTE associated harm is underappreciated among hospitalized patients and may be associated with missed doses of VTE prophylaxis medications.
- Trial name
- ENACT (NCT03367364)
- Testing
- Patient education bundle (PEB),, Nurse feedback and coaching (NFC)
- Where
- United States
- Volunteers
- 9,657 people
- Sponsor
- Johns Hopkins University
Venous Thromboembolism
Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery
The primary objective is to evaluate the efficacy of once daily (QD) subcutaneous (SC) injections of Semuloparin sodium (AVE5026) versus placebo for 3 additional weeks following an initial 7 to 10-day venous thromboprophylaxis…
- Trial name
- SAVE-HIP3 (NCT00709904)
- Testing
- Open-label Semuloparin sodium, Semuloparin sodium
- Where
- 16 sites in United States, Belarus and 14 more
- Volunteers
- 469 people
- Sponsor
- Sanofi
Venous Thromboembolism
Postpartum Heparin Against Venous Thromboembolism: a Pilot Randomized Controlled Trial
In previous attemps to answer the question of risk-benefit of postpartum thromboprophylaxis, researchers were faced with low recruitement rates.
- Trial name
- PP-HEP (NCT05878899)
- Testing
- Enoxaparin
- Where
- Switzerland
- Volunteers
- 77 people
- Sponsor
- University Hospital, Geneva
Venous Thromboembolism
Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs
To assess the safety and pharmacokinetics of DU-176b administered to patients with severe renal impairment undergoing orthopedic surgery of the lower limbs, compared with DU-176b administered to patients with mild renal…
- Trial name
- NCT01857583
- Testing
- 15mg DU-176b, 30mg DU-176b, Fondaparinux
- Where
- Japan
- Volunteers
- 80 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Venous Thromboembolism, Postpartum Period
The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity
The goal of the PARTUM trial is to determine if taking low-dose aspirin daily for 6 weeks after delivery is similar (non-inferior) to usual care low-molecular-weight heparin injections to prevent venous thromboembolism (VTE…
- Conditions
- Venous Thromboembolism, Postpartum Period, Aspirin, Low Molecular Weight Heparin
- Trial name
- NCT06494878
- Testing
- Aspirin, Low-molecular-weight heparin
- Where
- 12 sites in Belgium, Canada and 5 more
- Volunteers
- 8,805 people
- Sponsor
- University of Calgary
Venous Thromboembolism
Pharmacokinetic (PK) Assessment of BIBR 1048 in Patients After Primary Elective Total Hip Replacement Surgery
To determine the PK profile of a single dose 150 mg BIBR 1048, oral capsule, administered 1-3 hours post surgery in hip replacement patients.
- Trial name
- NCT02170935
- Testing
- BIBR 1048 capsule
- Volunteers
- 62 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism
VTE Prevention Following Total Hip and Knee Arthroplasty
Consented patients undergoing elective total hip and total knee arthroplasty will be randomized to receive either aspirin alone or aspirin and rivaroxaban for prevention of venous thromboembolism.
- Trial name
- EPCATIII (NCT04075240)
- Testing
- Rivaroxaban 10 MG and acetylsalicylic acid 81 mg, acetylsalicylic acid 81 mg
- Where
- Canada
- Volunteers
- 5,429 people
- Sponsor
- Sudeep Shivakumar
Obesity, Venous Thrombosis
Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT
Deep vein thrombosis(DVT) is a common complication in hospitalized medical patients. Consensus guidelines recommend using medications such as heparin or low-molecular-weight heparins (LMWH) to prevent DVT in these patients.
- Conditions
- Obesity, Venous Thrombosis, Anticoagulants
- Trial name
- NCT00585182
- Testing
- Enoxaparin 0.5 mg/kg once daily
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Utah
Venous Thromboembolism, Deep Vein Thrombosis
SToP: Venous Thromboembolism Screening in the Trauma Population
This is a prospective, randomized vanguard trial of trauma patients admitted to the trauma surgery service at Intermountain Medical Center who are deemed to be at high risk for venous thromboembolism.
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis, Trauma, Multiple
- Trial name
- SToP (NCT02978950)
- Testing
- Duplex ultrasound surveillance, No ultrasound surveillance
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Intermountain Health Care, Inc.
Neoplasms, Embolism
Anticoagulation in Patients With Venous Thromboembolism and Cancer
This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect…
- Trial name
- VICTORIE (NCT04618913)
- Testing
- Apixaban, Rivaroxaban, Edoxaban
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Pfizer
Sinus Thrombosis, Intracranial
Thrombolysis or Anticoagulation for Cerebral Venous Thrombosis
Background: Endovascular thrombolysis, with or without mechanical clot removal (ET), may be beneficial for a subgroup of patients with cerebral venous sinus thrombosis (CVT), who have a poor prognosis despite treatment with…
- Trial name
- TOACT (NCT01204333)
- Testing
- Endovascular thrombolysis, Heparin
- Where
- 15 sites in Canada, China and 4 more
- Volunteers
- 67 people
- Sponsor
- Jan Stam, MD, PhD
Burns
Efficacy and Safety for Different Regimen of VTE Pharmacoprophylaxis Among Severely Burn Patients
This study aims to assess the feasibility and safety of VTE prophylaxis for 3 modality regimens (Unfractionated heparin 5000 U SQ q8 hours, Enoxaparin 40 mg SQ q24 hours or Enoxaparin 30 mg SQ q12 hours) in adult patients (≥18…
- Trial name
- NCT05237726
- Testing
- Enoxaparin 40 mg q24 hours, Enoxaparin 30 mg q12 hours, Unfractionated heparin 5000 U q8 hours
- Where
- Saudi Arabia
- Volunteers
- 20 people
- Sponsor
- King Abdullah International Medical Research Center
VTE (Venous Thromboembolism), Phantom Limb Pain After Amputation
Venous Thromboembolism and Chronic Pain After Major Limb Trauma
Major limb trauma is associated with a high risk of venous thromboembolism (VTE) due to systemic inflammation, endothelial injury, immobilization, and hypercoagulability.
- Conditions
- VTE (Venous Thromboembolism), Phantom Limb Pain After Amputation, Chronic Pain, Chronic Pain Due to Injury
- Trial name
- THROMBO-PAIN (NCT07475910)
- Where
- Ukraine
- Volunteers
- 150 people
- Sponsor
- Charitable Organisation Charitable Fund Superhumans (Co Cf Superhumans)
Symptomatic Venous Thromboembolism (VTE)
REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called Acetylsalicylic Acid (ASA).
- Trial name
- ROXI-ASPEN (NCT07213778)
- Testing
- REGN7508, Acetylsalicylic Acid (ASA)
- Where
- 51 sites in United States, Greece and 3 more
- Volunteers
- 2,000 people
- Sponsor
- Regeneron Pharmaceuticals
Cancer, Deep Venous Thrombosis
Cohort Study to Identify Cancer Patients at High Risk of Venous Thromboembolism
Cancer patients are at increased risk of deep venous thrombosis and pulmonary embolism, collectively termed venous thromboembolism (VTE).
- Conditions
- Cancer, Deep Venous Thrombosis, Pulmonary Embolism
- Trial name
- MICA (NCT02095925)
- Where
- 7 sites in France, Italy and 2 more
- Volunteers
- 900 people
- Sponsor
- Harry R. Buller
Vascular Diseases, Embolism and Thrombosis
Epidemiology of Thromboembolism Disease: A Cohort Study
The purpose of this study is to determine different risk factors of thromboembolic disease. Different points will be studied 1. do different types of thromboembolic disease (distal Deep Vein Thrombosis (DVT), proximal DVT…
- Conditions
- Vascular Diseases, Embolism and Thrombosis, Phlebitis, Venous Insufficiency
- Trial name
- OPTIMEV (NCT00670540)
- Testing
- procedure of Deep Vein Thrombosis (DVT) and PE (Pulmonary Embolism) diagnosis
- Where
- 231 sites in Belgium, France and 1 more
- Volunteers
- 8,256 people
- Sponsor
- University Hospital, Grenoble
Thromboembolism, Cancer
Study on Impact of Edoxaban Treatment in Cancer Patients With Venous Thromboembolism During Antineoplastic Therapy
This is a multicentric, phase IV study. In this study patients that are receiving an antineoplastic treatment and that have been diagnosed with venous thromboembolism will receive edoxaban as per clinical practice.
- Trial name
- EDOI (NCT04072068)
- Testing
- Edoxaban
- Where
- 18 sites in Italy
- Volunteers
- 150 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Inferior Vena Cava Thrombosis, Venous Thromboembolism
Evaluation of Patients With Vena Cava Inferior Thrombosis
The purpose of the study is to evaluate patients with inferior vena cava (IVC)thrombosis in terms of etiology, clinical course and prognosis during long-term follow-up.
- Trial name
- NCT00631423
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Venous Thromboembolism
the Effectiveness of Different Risk Scales In Predicting VTE in Respiratory Inpatients
To compare the predictive effectiveness of the Caprini risk assessment model, the Padua risk assessment model and the VTE risk assessment in medical patients mentioned in the 2018 edition of the Guidelines for the diagnosis…
- Trial name
- NCT04963374
- Testing
- risk evolution scale
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University Third Hospital
Venous Thromboembolism
A Two-Part Study to Assess the Safety, Tolerability, PK and PD of ONO-7684 in Healthy Adult Volunteers
This is a first in human study to determine the safety, tolerability, pharmacokinetics and pharmacodynamics of ONO-7684 in healthy adult volunteers.
- Trial name
- NCT03919890
- Testing
- ONO-7684
- Where
- United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Ono Pharmaceutical Co., Ltd.